Basit öğe kaydını göster

dc.contributor.authorSandbergen, Laura
dc.contributor.authorGüven, Selçuk
dc.contributor.authordel Pilar Laguna Pes, Maria
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:51:42Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:51:42Z
dc.date.issued2019en_US
dc.identifier.citationSandbergen, L., Güven, S. ve del Pilar Laguna Pes, M. (2019). Can ablation win against partial nephrectomy and become first line therapy in cT1a renal tumours? Current Opinion in Urology, 29(1), 70-77. https://dx.doi.org/10.1097/MOU.0000000000000559en_US
dc.identifier.issn0963-0643
dc.identifier.issn1473-6586
dc.identifier.urihttps://dx.doi.org/10.1097/MOU.0000000000000559
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2269
dc.descriptionWOS: 000467768700011en_US
dc.descriptionPubMed ID: 30308573en_US
dc.description.abstractPurpose of review Currently, small renal masses account for the largest proportion of renal tumour and small renal cell carcinomas (RCC). Although partial nephrectomy, whenever possible, is recognized as the gold standard for treatment, thermal ablation has gained increasing attention as optional treatment in a population sector harbouring small renal masses/small RCCs. The purpose of this review is to update comparative outcomes between these two options of treatment. Recent findings Recent observational case-control and population-based cohorts applying propensity score or inverse probability treatment weighted methodology adjusting for baseline patient and tumour characteristics, compare outcomes between partial nephrectomy and thermal ablation (both cryotherapy and radiofrequency), radical nephrectomy and thermal ablation and between thermal ablation and nonsurgical management. Most of them focus on T1aRCC. Summary Comparative outcomes' evidence is limited to population-based or institutional series adjusted for baseline differences and systematic reviews. With exception of special clinical situations, thermal ablation provides similar estimated 5-year cancer and overall survival with a clear benefit in postoperative outcomes when compared to partial nephrectomy in cT1a older patients. The trade-off is more evident when thermal ablation is compared to radical nephrectomy. The advantages in terms of adverse events persist up to 1 year after treatment. Benefits are less apparent in solitary kidneys and when synchronous bilateral approaches are performed.en_US
dc.description.sponsorshipCure for Cancer foundation (Amsterdam, the Netherlands)en_US
dc.description.sponsorshipL.S. is a PhD student supported by Cure for Cancer foundation (Amsterdam, the Netherlands).en_US
dc.language.isoengen_US
dc.publisherLippincott Williams and Wilkinsen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectCryoablationen_US
dc.subjectCT1a Renal Massen_US
dc.subjectLocalized Renal Massen_US
dc.subjectMinimally Invasive Surgeryen_US
dc.subjectPartial Nephrectomyen_US
dc.subjectPercutaneous Ablationen_US
dc.subjectRadiofrequencyen_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectRoboticen_US
dc.subjectSmall Renal Massesen_US
dc.subjectThermal Ablationen_US
dc.titleCan ablation win against partial nephrectomy and become first line therapy in cT1a renal tumours?en_US
dc.typereviewen_US
dc.relation.ispartofCurrent Opinion in Urologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalıen_US
dc.authorid0000-0002-5009-8435en_US
dc.authorid0000-0003-0906-4417en_US
dc.identifier.volume29en_US
dc.identifier.issue1en_US
dc.identifier.startpage70en_US
dc.identifier.endpage77en_US
dc.relation.publicationcategoryDiğeren_US
dc.identifier.doi10.1097/MOU.0000000000000559en_US
dc.identifier.wosqualityQ3en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster